Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|November 2, 2020
[Pharmacological properties and clinical efficacy of dotinurad (URECE® tablets), a novel hypouricemic agent]Tetsuya Taniguchi, Naoki Ashizawa
Nucleosides, Nucleotides & Nucleic Acids|June 30, 2022
An evaluation method for uric acid uptake inhibition using primary human proximal tubule epithelial cells treated with insulinJunichiro Uda, Naoki Ashizawa, Takashi Iwanaga
Naunyn-Schmiedeberg'S Archives of Pharmacology|December 10, 2016
Enhancement of pharmacological effects of uricosuric agents by concomitant treatment with pyrazinamide in ratsTetsuya Taniguchi, Naoki Ashizawa, Koji Matsumoto, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 19, 2010
FYX-051: a novel and potent hybrid-type inhibitor of xanthine oxidoreductaseKoji Matsumoto, Ken Okamoto, Naoki Ashizawa, et al.
Bioorganic & Medicinal Chemistry Letters|March 8, 2021
Novel monocyclic amide-linked phenol derivatives without mitochondrial toxicity have potent uric acid-lowering activityJunichiro Uda, Seiichi Kobashi, Naoki Ashizawa, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|June 4, 2005
Simultaneous treatment with citrate prevents nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor, in ratsTakeo Shimo, Naoki Ashizawa, Koji Matsumoto, et al.
Drug and Chemical Toxicology|February 15, 2011
Study on toxicological aspects of crystal-mediated nephrotoxicity induced by FYX-051, a xanthine oxidoreductase inhibitor, in ratsTakeo Shimo, Mitsuyoshi Moto, Naoki Ashizawa, et al.
Archives of Toxicology|October 12, 2010
Study on species differences in nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitorTakeo Shimo, Naoki Ashizawa, Mitsuyoshi Moto, et al.
The Journal of Pharmacy and Pharmacology|November 22, 2015
Uricosuric agents decrease the plasma urate level in rats by concomitant treatment with topiroxostat, a novel xanthine oxidoreductase inhibitorTetsuya Taniguchi, Naoki Ashizawa, Koji Matsumoto, et al.
The Journal of Pharmacy and Pharmacology|April 21, 2021
Assessment of calciprotein particle formation by AUC of the absorbance change: effect of FYB-931, a novel bisphosphonate compoundKoichi Ishida, Naoki Ashizawa, Shota Morikane, et al.
Pageof 5